Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase

BE0009519ProteinHumansPKMYT1

Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins (PubMed:10373560, PubMed:10504341, PubMed:9001210, PubMed:9268380). It is acted on by 2 drugs in DrugBank.

Gene name
PKMYT1
UniProtKB entry
Q99640Swiss-Prot
Cellular location
Endoplasmic reticulum membrane
Residues / weight
499 residues · 54,521 Da
Also known as
2.7.11.1 · MYT1 · Myt1 kinase

Resolves to

Protein
UniProtQ99640UniProt namePMYT1_HUMAN
Gene
HGNCHGNC:29650NCBI Gene9088GeneCardsPKMYT1
Pharmacology
IUPHAR/GtoPdb2167KEGGhsa:9088
Structure
PDB23ESPDB23FWPDB3P1A
Drugs

What you can answer from here — as of September 07, 2019

2DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
5GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
20+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In